Alder L et al. Durable clinical and radiographic responses in a series of patients with HER2+ breast cancer (BC) leptomeningeal disease (LMD) treated with trastuzumab deruxtecan (T-DXd). AACR 2022;Abstract 5257.
Brastianos PK et al. Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. Nat Commun 2021;12(1):5954. Abstract
Corti C et al. Targeting brain metastases in breast cancer. Cancer Treat Rev 2022;103:102324. Abstract
Gion M et al. Systemic therapy for HER2-positive metastatic breast cancer: Moving into a new era. Am Soc Clin Oncol Educ Book 2022;42:1-11. Abstract
Giordano SH et al. Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update. J Clin Oncol 2022;40(23):2612-35. Abstract
Leone JP et al. Factors associated with short- and long-term survival in metastatic HER2+ breast cancer. ASCO 2022;Abstract 1047.
Lin NU et al. Central nervous system metastases as a site of first recurrence in adjuvant therapy trials of HER2+ early breast cancer (EBC). SABCS 2021;Abstract P2-13-05.
Lin NU et al. Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases (HER2CLIMB). SABCS 2021;Abstract PD4-04.
Ma CX et al. The phase II MutHER study of neratinib alone and in combination with fulvestrant in HER2-mutated, non-amplified metastatic breast cancer. Clin Cancer Res 2022;28(7):1258-67. Abstract
Murthy RK et al. Safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis (LM) in HER2-positive breast cancer: Results from TBCRC049, a phase 2 non-randomized study. SABCS 2021;Abstract PD4-02.
Ramakrishna N et al. Management of advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO guideline update. J Clin Oncol 2022;40(23):2636-55. Abstract
Tarantino P et al. Aiming at a tailored cure for ERBB2-positive metastatic breast cancer: A review. JAMA Oncol 2022;8(4):629-35. Abstract
Tarantino P et al. Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer. JAMA Oncol 2022;8(8):1177-83. Abstract